
Intuitive Surgical (ISRG) Stock Forecast & Price Target
Intuitive Surgical (ISRG) Analyst Ratings
Bulls say
Intuitive Surgical has demonstrated robust growth in its Ion and SP system installations, with Ion utilization rising by 14% and SP utilization increasing by 35%, contributing to an expanding installed base that underscores the company’s market penetration. The improvement in gross margin guidance to 67-67.5% due to higher US system placements and favorable tariff outlook highlights Intuitive Surgical's operational efficiency and profitability potential. Additionally, the increasing Da Vinci system utilization, particularly driven by the adoption of the D5 model among surgeons, suggests a positive trend in procedural growth, reinforcing the company's strong market position.
Bears say
Intuitive Surgical's recent financial performance indicates several challenges that contribute to a negative outlook on its stock. Revenue from services was slightly below expectations at $396 million, and there is significant concern about the impact of macroeconomic factors on hospital capital budgets, which could restrain future robotic system purchases. Additionally, the company faces ongoing resistance from markets and physicians towards adopting newer robotic surgical technologies, combined with a prolonged rollout of next-generation systems and issues related to third-party instrument reprocessing affecting consumable sales.
This aggregate rating is based on analysts' research of Intuitive Surgical and is not a guaranteed prediction by Public.com or investment advice.
Intuitive Surgical (ISRG) Analyst Forecast & Price Prediction
Start investing in Intuitive Surgical (ISRG)
Order type
Buy in
Order amount
Est. shares
0 shares